These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26957610)

  • 1. Somatostatin Analogues in Neuroendocrine Tumors.
    Kulke MH
    J Natl Compr Canc Netw; 2016 Mar; 14(3):241-2. PubMed ID: 26957610
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses.
    de Herder WW; Lamberts SW
    Curr Opin Oncol; 2002 Jan; 14(1):53-7. PubMed ID: 11790981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumour vanishes.
    Todd JF; Meeran K
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).
    Adelman D; Truong Thanh XM; Feuilly M; Houchard A; Cella D
    Adv Ther; 2020 Apr; 37(4):1608-1619. PubMed ID: 32157626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary: Somatostatin analogs-How we choose, and why.
    Reidy-Lagunes D; Raj N; Saltz L
    Semin Oncol; 2017 Apr; 44(2):157-158. PubMed ID: 28923214
    [No Abstract]   [Full Text] [Related]  

  • 7. Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement.
    Chin SO; Ku CR; Kim BJ; Kim SW; Park KH; Song KH; Oh S; Yoon HK; Lee EJ; Lee JM; Lim JS; Kim JH; Kim KJ; Jin HY; Kim DJ; Lee KA; Moon SS; Lim DJ; Shin DY; Kim SH; Kwon MJ; Kim HY; Kim JH; Kim DS; Kim CH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):53-62. PubMed ID: 30912339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours.
    Shah T; Caplin M
    Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):617-36. PubMed ID: 16183531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Established clinical use of octreotide and lanreotide in oncology.
    Oberg K
    Chemotherapy; 2001; 47 Suppl 2():40-53. PubMed ID: 11275701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P
    Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic strategies for neuroendocrine tumours--can eminence replace evidence?
    Zedenius J
    Acta Oncol; 2008; 47(1):3-4. PubMed ID: 17891671
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
    Gut P; Ruchała M
    Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
    Saveanu A; Gunz G; Dufour H; Enjalbert A; Culler MD; Jaquet P
    J Endocrinol Invest; 2003; 26(8 Suppl):4-7. PubMed ID: 15233203
    [No Abstract]   [Full Text] [Related]  

  • 17. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin agonists for treatment of acromegaly.
    Ben-Shlomo A; Melmed S
    Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.
    D'Angelillo RM; Greco C; Fiore M; Ippolito E; Eolo Trodella L; Iurato A; Molfese E; Ramella S; Trodella L
    Tumori; 2014; 100(3):249-53. PubMed ID: 25076233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.